About Surrozen
Surrozen is a publicly listed company based in San Francisco (United States) founded in 2016. Selective Wnt agonists are developed for human tissue regeneration. Surrozen has raised $133 million across 5 funding rounds from investors including RA Capital, Hartford HealthCare and The Column Group. The company has 41 employees. Surrozen offers products and services including Wnt Biology Platform and SWAP/SWEETS. Its focus areas include Biopharma Outsourcing, Diversified and Biologics. Its competitors include Catalent, Curia and AmplifyBio; 1 of its 3 listed competitors has raised funding.
Company details
Surrozen was founded in 2016 and is headquartered in San Francisco, United States. Protein therapeutics targeting the Wnt pathway are discovered and developed to support tissue repair and regeneration. A pipeline of selective agonists is constructed to enable in situ regeneration across various tissues. Roles of Wnt proteins in stem cell maintenance and developmental processes are leveraged within the biotechnology sector.
- Headquarters San Francisco, United States
- Employees 41
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website surrozen.com
- Social LinkedIn
- Legal Name Surrozen, Inc.
- Annual Revenue$3.48 M (USD)-67.37as on Dec 31, 2025
- Net Profit-$242.03 M (USD)-280.76as on Dec 31, 2025
- EBITDA-$41.55 M (USD)-72.45as on Dec 31, 2025
- Total Equity Funding$133M (USD)
in 5 rounds
- Latest Funding Round$175M (USD), Post-IPO
Mar 2025
- InvestorsRA Capital
& 13 more
- Employee Count41
Products & Services of Surrozen
Surrozen offers a comprehensive portfolio of products and services, including Wnt Biology Platform and SWAP/SWEETS.
Platform for unlocking body's regenerative power to treat injuries and diseases
Technology for advancing treatments in regenerative medicine and disease pipelines
Funding Insights of Surrozen
Surrozen has successfully raised a total of $133M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $175 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $133M
- Total Rounds 5
- Last Round Post-IPO — $175M
- First Round $33M
(Feb 2017)
- Investors Count 14
All 5 funding rounds of Surrozen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2025 | $175M | Post-IPO | – | Venrock | |
| Apr 2024 | $193.02M | Post-IPO | – | – | – |
| Jun 2020 | $50M | Series C | – | TCG, Horizons Ventures | – |
| Mar 2019 | $50M | Series B | – | Horizons Ventures, Timefolio Capital | – |
| Feb 2017 | $33M | Series A | – | TCG | – |
14 investors in total: 14 institutional.
Investors in Surrozen
Surrozen has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, Hartford HealthCare and The Column Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
Access Biotechnology is engaged in investing in transformative biopharma therapies. | 1986 | accessbio-tech.com | New York, United States | |
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Horizons Ventures is focused on investing in deep science and technology. | horizonsventures.com | Hong Kong, China | ||
Venture capital firm focused on therapeutics drugs | timefoliocapital.co.kr | Seoul, South Korea | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Provides financial investments to healthcare firms for health and well-being innovation. | 2015 | acutacapital.com | Belmont, United States |
Investor details for Surrozen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Surrozen
33 people are tracked at Surrozen (13 in leadership, 14 in board & advisors, 6 in team); the tracked headcount is 41.
| Name | Role | Group |
|---|---|---|
Craig Parker | Chief Executive Officer | Leadership |
Charles Williams | Chief Operating Officer | Leadership |
Dave Nakamura | VP Of Information Technology & Site Operations | Leadership |
Jay Villaluna | Associate Director, IT Infrastructure and Operations | Leadership |
Peter Stathis | Head Of Technical Operations | Leadership |
Andrew Maleki | Chief Financial Officer | Leadership |
Esther Jhun | VP Of Finance And Controller | Leadership |
Kimberly Guardado | Associate Director Of Benefits & Operations | Leadership |
Jeff Ho | VP Corporate Development and Strategy | Leadership |
Tracy Chen | Head of Quality | Leadership |
Candra Canning | Head of Culture and Leadership | Leadership |
Michael Lauw | Vice President, Development Operations | Leadership |
Trudy Vanhove | Chief Medical Officer | Leadership |
Mary Haak-Frendscho | Director | Board & advisors |
Tim Kutzkey | Chairman | Board & advisors |
Bart Williams | Advisor | Board & advisors |
Chris Chai | Director | Board & advisors |
Calvin Kuo | Advisor | Board & advisors |
Shao-Lee Lin | Director | Board & advisors |
Harold Varmus | Advisor | Board & advisors |
13 more people are available in the full profile.
Complete people profiles for Surrozen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Surrozen
Surrozen is a publicly listed company on the NASDAQ with ticker symbol SRZN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Aug 2021
- Listed onNASDAQ: SRZN
- Listed entitySurrozen, Inc.
- Exchange sectorHealth technology
- ISINUS86889P2083
- Share price$23.51 (-5.05% on the day) · 2026-10-13
- Market capitalisation$276.3M
- EPS (diluted, trailing year)$-44.28
- Volume (last session)868,789
Financials of Surrozen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $3.5M | -$242.0M | -$41.5M |
| 2024 | $10.7M | -$63.6M | -$24.1M |
| 2023 | -$43.0M | -$41.1M | |
| 2022 | $12.5M | -$36.0M | -$41.1M |
| 2021 | -$54.6M | -$51.1M |
Detailed financial statements for Surrozen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Surrozen
4 dated milestones of Surrozen across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Surrozen is founded.
- Funding First funding round of $33.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $175.0M.
Competitors of Surrozen
Surrozen has 3 listed competitors in our database, 1 of them funded. They include Catalent, Curia and AmplifyBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| catalent.com | 2007 | Somerset, United States | 9,390 | CDMO offering drug and biologics development services | ||
| curiaglobal.com | 1991 | Albany, United States | 1,918 | Drug research, development, testing, and consulting services are provided. | ||
| amplify-bio.com | 2021 | Hilliard, United States | $229.75M | Provides contract research, development, and manufacturing services for biologic drugs. |
Detailed competitors of Surrozen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Surrozen
The website of Surrozen (surrozen.com) receives about 8.5K visits a month and ranks #3,931,985 among all websites worldwide, #4,972 in Biotechnology and Pharmaceuticals.
- Monthly visits8.5K
▲ 85.6% vs previous month
- Unique visitors1.9K
per month
- Global rank#3,931,985
among all websites
- Category rank#4,972
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.9
- Average visit39 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with Surrozen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| endpts.com | 100% | 8.4K | #3,077,209 | View details | |
| fiercebiotech.com | 80% | 858.3K | #81,022 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Surrozen (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Surrozen
Complete news archive for Surrozen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Surrozen
Surrozen was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Surrozen is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Surrozen is a funded company, having raised a total of $133M across 5 funding rounds to date. The company's 1st funding round was a Series A of $33M, raised on Feb 2017.
Surrozen has 41 employees.
Annual revenue of Surrozen is $3.48M as on Dec 31, 2025.
Surrozen was founded in 2016 and is headquartered in San Francisco, United States. Protein therapeutics targeting the Wnt pathway are discovered and developed to support tissue repair and regeneration. A pipeline of selective agonists is constructed to enable in situ regeneration across various tissues. Roles of Wnt proteins in stem cell maintenance and developmental processes are leveraged within the biotechnology sector.
Surrozen's top competitors include Catalent, Curia and AmplifyBio.
Surrozen offers Wnt Biology Platform and SWAP/SWEETS.
Yes, Surrozen is publicly traded on NASDAQ under the ticker symbol SRZN.
Surrozen has 14 investors. Key investors include RA Capital, Hartford HealthCare, The Column Group, Venrock, and Access Biotechnology.